Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07568236 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jul 1, 2026 to Oct 5, 2026 · Eligibility criteria expanded, about 9 words · Secondary endpoints: details revised at 3 of 6 entries · 2 more Show 5 more changesShow less
    • Start date changed from estimate of Jul 1, 2026 to Oct 5, 2026
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Site details revised
    • Publications: details revised at 6 of 7 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
Trial Details
NCT Number NCT07568236
Lead Sponsor Chinese University of Hong Kong
Conditions Vasomotor Symptoms, Prostate Cancer
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov